title: HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone.
abstract: Mechanisms underlying fetal hemoglobin (HbF) reactivation in stress erythropoiesis have not been fully elucidated. We suggested that a key role is played by kit ligand (KL). Because glucocorticoids (GCs) mediate stress erythropoiesis, we explored their capacity to potentiate the stimulatory effect of KL on HbF reactivation, as evaluated in unilineage erythropoietic culture of purified adult progenitors (erythroid burst-forming units [BFU-Es]). The GC derivative dexamethasone (Dex) was tested in minibulk cultures at graded dosages within the therapeutical range (10(-6) to 10(-9) M). Dex did not exert significant effects alone, but synergistically it potentiated the action of KL in a dose-dependent fashion. Specifically, Dex induced delayed erythroid maturation coupled with a 2-log increased number of generated erythroblasts and enhanced HbF synthesis up to 85% F cells and 55% gamma-globin content at terminal maturation (ie, in more than 80%-90% mature erythroblasts). Equivalent results were obtained in unicellular erythroid cultures of sibling BFU-Es treated with KL alone or combined with graded amounts of Dex. These results indicate that the stimulatory effect of KL + Dex is related to the modulation of gamma-globin expression rather than to recruitment of BFU-Es with elevated HbF synthetic potential. At the molecular level, Id2 expression is totally suppressed in control erythroid culture but is sustained in KL + Dex culture. Hypothetically, Id2 may mediate the expansion of early erythroid cells, which correlates with HbF reactivation. These studies indicate that GCs play an important role in HbF reactivation. Because Dex acts at dosages used in immunologic disease therapy, KL + Dex administration may be considered to develop preclinical models for beta-hemoglobinopathy treatment.
authors.affiliation: Department of Hematology and Oncology, Istituto Superiore di Sanità, Rome, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Gabbianelli
authors.forename: Ugo
authors.initials: U
authors.lastname: Testa
authors.forename: Adriana
authors.initials: A
authors.lastname: Massa
authors.forename: Ornella
authors.initials: O
authors.lastname: Morsilli
authors.forename: Ernestina
authors.initials: E
authors.lastname: Saulle
authors.forename: Nadia Maria
authors.initials: NM
authors.lastname: Sposi
authors.forename: Eleonora
authors.initials: E
authors.lastname: Petrucci
authors.forename: Gualtiero
authors.initials: G
authors.lastname: Mariani
authors.forename: Cesare
authors.initials: C
authors.lastname: Peschle
mesh_terms: D018929:Cell Culture Techniques; D002455:Cell Division / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D015672:Erythroid Precursor Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004920:Erythropoiesis / Q000187:drug effects; D005319:Fetal Hemoglobin / Q000096:biosynthesis* / Q000187:drug effects; D005914:Globins / Q000032:analysis; D006801:Humans; D000860:Hypoxia; D007700:Kinetics; D008297:Male; D019089:Stem Cell Factor / Q000494:pharmacology*; D014157:Transcription Factors / Q000032:analysis
chemical_list: D019089:Stem Cell Factor; D014157:Transcription Factors; D003907:Dexamethasone; D005914:Globins; D005319:Fetal Hemoglobin